The meta-analysis based on recent clinical trials revealed that the high/positive expression of PD-L1 predicted better 6- and 12-month OS in HNSCC (RR 1.30; 95% CI: 1.02–1.65, p = 0.03; and RR 1.31, 95% CI: 1.05–1.62, p = 0.01). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.